Communiqués Formosa Pharmaceuticals, Inc.

Actions

Cours en clôture Taiwan S.E. 04/09/2026			Varia. 5j.	Varia. 1 janv.
24,65 ^TWD	+2,71%		+7,17%	-6,63%

28/08	Formosa Pharmaceuticals dépose une demande d'essai clinique pour le TSY-110, un biosimilaire de conjugué anticorps-médicament ciblant les cancers du sein HER2-positifs	CI
24/08	Formosa Pharmaceuticals : son partenaire dépose une demande d'homologation auprès des autorités sanitaires australiennes	MT

31/08	Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers	AQ
21/05	Formosa Pharmaceuticals Announces Presentation of TSY-310 at the 2026 ASCO Annual Meeting	PR
09/06/25	Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals	BU
29/11/24	Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain	AQ
05/11/24	Formosa Pharmaceuticals Announces Successful Top-Line Results from CPN-303, a Phase 3 Trial in Chinese Subjects for the Treatment of Inflammation and Pain after Cataract Surgery	AQ
08/10/24	Post-Operative Cataract Surgery Inflammation Pipeline, Treatment Drugs, Clinical Trials, and Companies 2024	AQ
09/09/24	Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization	PR
06/08/24	Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery	AQ
10/05/24	Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals	AQ